Silence Therapeutics Plc American Depository Share (SLN)
Company News
The Australia ARDS market is projected to grow from USD 24.82 million in 2024 to USD 44.79 million by 2033, driven by rising respiratory diseases, technological innovations, and post-COVID lung damage awareness.
Silence Therapeutics (NASDAQ:SLN) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewh...
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
SLN earnings call for the period ending June 30, 2021.